|
1
|
Adewuyi O‘S, Balogun MS, Otomaru H, Abimiku A, Ahumibe AA, Ilori E, Luong QA, Mba N, Avong JC, Olaide J, Okunromade O, Ahmad A, Akinpelu A, Ochu CL, Olajumoke B, Abe H, Ihekweazu C, Ifedayo A, Toizumi M, Moriuchi H, Yanagihara K, Idris J, Yoshida LM. Molecular Epidemiology, Drug-Resistant Variants, and Therapeutic Implications of Hepatitis B Virus and Hepatitis D Virus Prevalence in Nigeria: A National Study. Pathogens 2025; 14:101. [PMID: 39861062 PMCID: PMC11768191 DOI: 10.3390/pathogens14010101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2024] [Revised: 01/12/2025] [Accepted: 01/13/2025] [Indexed: 01/27/2025] Open
Abstract
Information on circulating HBV (sub-)genotype, variants, and hepatitis D virus (HDV) coinfection, which vary by geographical area, is crucial for the efficient control and management of HBV. We investigated the genomic characteristics of HBV (with a prevalence of 8.1%) and the prevalence of HDV in Nigeria. We utilised 777 HBV-positive samples and epidemiological data from the two-stage sampled population-based, nationally representative Nigeria HIV/AIDS Indicator and Impact Survey conducted in 2018. We assessed 732 HBV DNA-extracted samples with detectable viral loads (VLs) for (sub-)genotypes and variants by whole-genome pre-amplification, nested PCR of the s-and pol-gene, and BigDye Terminator sequencing. We conducted HDV serology. In total, 19 out of the 36 + 1 states in Nigeria had a high prevalence of HBV (≥8%), with the highest prevalence (10.4%) in the north-central geopolitical zone. Up to 33.2% (95% CI 30.0-36.6) of the participants had detectable VLs of ≥300 copies/mL. The predominant circulating HBV genotype was E with 98.4% (95% CI 97.1-99.1), followed by A with 1.6% (95% CI 0.9-2.9). Drug-resistant associated variants and immune escape variants were detected in 9.3% and 0.4%, respectively. The seroprevalence of HDV was 7.34% (95% CI 5.5-9.2). Nigeria has subtype E as the major genotype with many variants.
Collapse
Affiliation(s)
- Oludare ‘Sunbo Adewuyi
- Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan (H.M.)
- Department of Paediatric Infectious Diseases, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan (M.T.)
- Nigeria Centre for Disease Control and Prevention, Abuja 240102, Nigeria (O.O.); (C.L.O.)
| | - Muhammad Shakir Balogun
- Nigeria Field Epidemiology and Laboratory Training Programme, Abuja 900231, Nigeria;
- African Field Epidemiology Network, Asokoro, Abuja 900231, Nigeria
| | - Hirono Otomaru
- Department of Paediatric Infectious Diseases, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan (M.T.)
| | - Alash’le Abimiku
- Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - Anthony Agbakizu Ahumibe
- Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan (H.M.)
- Nigeria Centre for Disease Control and Prevention, Abuja 240102, Nigeria (O.O.); (C.L.O.)
| | - Elsie Ilori
- Nigeria Centre for Disease Control and Prevention, Abuja 240102, Nigeria (O.O.); (C.L.O.)
| | - Que Anh Luong
- Department of Paediatric Infectious Diseases, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan (M.T.)
| | - Nwando Mba
- Nigeria Centre for Disease Control and Prevention, Abuja 240102, Nigeria (O.O.); (C.L.O.)
| | | | - John Olaide
- Department of Paediatric Infectious Diseases, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan (M.T.)
| | - Oyeladun Okunromade
- Nigeria Centre for Disease Control and Prevention, Abuja 240102, Nigeria (O.O.); (C.L.O.)
| | - Adama Ahmad
- Nigeria Centre for Disease Control and Prevention, Abuja 240102, Nigeria (O.O.); (C.L.O.)
| | - Afolabi Akinpelu
- Nigeria Centre for Disease Control and Prevention, Abuja 240102, Nigeria (O.O.); (C.L.O.)
| | - Chinwe Lucia Ochu
- Nigeria Centre for Disease Control and Prevention, Abuja 240102, Nigeria (O.O.); (C.L.O.)
| | - Babatunde Olajumoke
- Nigeria Centre for Disease Control and Prevention, Abuja 240102, Nigeria (O.O.); (C.L.O.)
| | - Haruka Abe
- Vietnam Research Station, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan
| | - Chikwe Ihekweazu
- Nigeria Centre for Disease Control and Prevention, Abuja 240102, Nigeria (O.O.); (C.L.O.)
- WHO Hub for Pandemic and Epidemic Intelligence, Prinzessinnenstrasse 17-18, 10969 Berlin, Germany
| | - Adetifa Ifedayo
- Nigeria Centre for Disease Control and Prevention, Abuja 240102, Nigeria (O.O.); (C.L.O.)
- Foundation for Innovative New Diagnostics, 1202 Geneva, Switzerland
| | - Michiko Toizumi
- Department of Paediatric Infectious Diseases, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan (M.T.)
- School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan
| | - Hiroyuki Moriuchi
- Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan (H.M.)
- School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan
- Department of Paediatrics, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan
| | - Katsunori Yanagihara
- Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan (H.M.)
- School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan
- Department of Laboratory Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan
| | - Jide Idris
- Nigeria Centre for Disease Control and Prevention, Abuja 240102, Nigeria (O.O.); (C.L.O.)
| | - Lay-Myint Yoshida
- Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan (H.M.)
- Department of Paediatric Infectious Diseases, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan (M.T.)
- School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan
| |
Collapse
|
|
2
|
Sukowati CHC, Jayanti S, Turyadi T, Muljono DH, Tiribelli C. Hepatitis B virus genotypes in precision medicine of hepatitis B-related hepatocellular carcinoma: Where we are now. World J Gastrointest Oncol 2024; 16:1097-1103. [PMID: 38660644 PMCID: PMC11037070 DOI: 10.4251/wjgo.v16.i4.1097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/04/2024] [Revised: 01/30/2024] [Accepted: 03/06/2024] [Indexed: 04/10/2024] Open
Abstract
Hepatitis B virus (HBV) infection is a major player in chronic hepatitis B that may lead to the development of hepatocellular carcinoma (HCC). HBV genetics are diverse where it is classified into at least 9 genotypes (A to I) and 1 putative genotype (J), each with specific geographical distribution and possible different clinical outcomes in the patient. This diversity may be associated with the precision medicine for HBV-related HCC and the success of therapeutical approaches against HCC, related to different pathogenicity of the virus and host response. This Editorial discusses recent updates on whether the classification of HBV genetic diversity is still valid in terms of viral oncogenicity to the HCC and its precision medicine, in addition to the recent advances in cellular and molecular biology technologies.
Collapse
Affiliation(s)
- Caecilia H C Sukowati
- Eijkman Research Center for Molecular Biology, Research Organization for Health, National Research and Innovation Agency of Indonesia, Jakarta 10340, Indonesia
- Liver Cancer Unit, Fondazione Italiana Fegato ONLUS, Trieste 34149, Italy
| | - Sri Jayanti
- Eijkman Research Center for Molecular Biology, Research Organization for Health, National Research and Innovation Agency of Indonesia, Jakarta 10340, Indonesia
| | - Turyadi Turyadi
- Eijkman Research Center for Molecular Biology, Research Organization for Health, National Research and Innovation Agency of Indonesia, Jakarta 10340, Indonesia
| | - David H Muljono
- Faculty of Medicine, Hasanuddin University, Makassar 90245, South Sulawesi, Indonesia
- Faculty of Medicine and Health, University of Sydney, Sydney 2050, Australia
| | - Claudio Tiribelli
- Liver Cancer Unit, Fondazione Italiana Fegato ONLUS, Trieste 34149, Italy
| |
Collapse
|
|
3
|
Chemin I, Pujol FH. Updates on Hepatitis B Virus (HBV) Infection 2.0. Microorganisms 2023; 11:2874. [PMID: 38138018 PMCID: PMC10746071 DOI: 10.3390/microorganisms11122874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Accepted: 11/25/2023] [Indexed: 12/24/2023] Open
Abstract
Hepatitis B is a "silent epidemic" that is fifty to a hundred (50-100) times more infectious than HIV and is a potentially life-threatening liver infection [...].
Collapse
Affiliation(s)
- Isabelle Chemin
- Institut National de la Santé et de la Recherche Médicale (Inserm) U1052, Centre de Recherche en Cancérologie de Lyon (CRCL), 151 Cours Albert Thomas, 69003 Lyon, France
| | - Flor Helene Pujol
- Laboratorio de Virología Molecular, Centro de Microbiología y Biología Celular (CMBC), Instituto Venezolano de Investigaciones Científicas (IVIC), Caracas 1020A, Venezuela
- Collegium de Lyon, Institut d’Etudes Avancées, Université Lyon 2, 69007 Lyon, France
| |
Collapse
|